NCT03696771View on ClinicalTrials.gov

Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

December 27, 2018

Primary Completion Date

October 19, 2020

Study Completion Date

October 19, 2020

Conditions
NON-breast HER2+ Malignancies
Interventions
DRUG

NJH395

Immune stimulator antibody conjugate (ISAC), consisting of a monoclonal antibody which targets HER2 conjugated to an immune-stimulatory agent

Trial Locations (4)

20162

Novartis Investigative Site, Milan

77030

University of Texas MD Anderson Cancer Center, Houston

277 8577

Novartis Investigative Site, Kashiwa

03080

Novartis Investigative Site, Seoul

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY